Jonathan S. Zager, MD, discussed the use of percutaneous hepatic perfusion vs best alternative care for patients with hepatic-dominant ocular melanoma analyzed in the phase 3 FOCUS trial.
Clinical Trials
Increased Melanoma Survival With Immunotherapy Followed by Targeted Therapy
A clinical trial led by clinicians at Georgetown Lombardi Comprehensive Cancer Center showed a remarkable 20 percent advantage in the two-year overall survival rate for people with advanced melanoma who first received immunotherapy (72 percent survival rate) versus those who initially got targeted therapies (52 percent survival rate). Progression-free survival, where the cancer is stable or improving, was also trending in favor of those who started on immunotherapy.
Immunotherapy Before Targeted Therapy Improves Survival in Advanced Melanoma
Combination PD-1/CTLA-4 blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in patients with BRAF V600 mutant metastatic melanoma.
A Phase I/II Study of IOV-4001 in People with Inoperable or Metastatic Melanoma or Non-Small Cell Lung Cancer
A Phase 1/2, Open-label Study of PD-1 Knockout Tumor-infiltrating Lymphocytes (IOV-4001) in Participants with Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer